Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746746 | 0.90 | OPRD1 (0.49) | CALCRLBACE1OPRD1OPRM1OPRK1 | |
| SCHEMBL29961965 | 0.90 | CALCRL (0.37) | CALCRLBACE1BACE2OPRD1OPRM1 | |
| SCHEMBL29882808 | 0.88 | OPRD1 (0.50) | BACE1OPRD1OPRM1OPRK1 | |
| SCHEMBL29456530 | 0.88 | OPRD1 (0.50) | BACE1OPRD1OPRM1OPRK1 | |
| SCHEMBL2742710 | 0.87 | CALCRL (0.37) | CALCRLBACE1BACE2OPRD1CASP3 | |
| SCHEMBL12873177 | 0.87 | CALCRL (0.37) | CALCRLBACE1BACE2OPRD1CASP3 | |
| SCHEMBL30475883 | 0.86 | PTPN1 (0.51) | CALCRLBACE1BACE2 | |
| SCHEMBL29546019 | 0.85 | MME (0.51) | — | |
| SCHEMBL12603082 | 0.85 | ERBB2 (0.39) | CALCRLBACE1BACE2 | |
| SCHEMBL31039959 | 0.85 | MME (0.45) | OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807674-B2 | Hepcidin analogues and uses thereof | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472842-B2 | Analogues of hepcidin mimetics with improved in vivo half lives | HAMP, VIP, HDGF | CALCRL 57/4885BACE1 1262/4885BACE2 1803/4885 |
| US-11807674-B2 | Hepcidin analogues and uses thereof | HAMP, SLC40A1, FTH1 | CALCRL 134/4885BACE1 1506/4885BACE2 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.